Acute myeloid Leukaemia
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- (no location specified)
Sep 18, 2023
Acute Myeloid Leukaemia Trial in Worldwide (S 64315 (also referred as MIK665) and azacitidine)
Active, not recruiting
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and azacitidine
-
Houston, Texas
- +6 more
Dec 16, 2022
Acute Myeloid Leukaemia Trial in Australia, France, United States (S 64315 (also referred as MIK665) and venetoclax)
Terminated
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and venetoclax
-
New Haven, Connecticut
- +6 more
Dec 20, 2022
Relapsed Acute Myeloid Leukaemia Trial (Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL))
Not yet recruiting
- Relapsed Acute Myeloid Leukaemia
- Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
- (no location specified)
Jul 4, 2023
Acute Myeloid Leukemia in Remission Trial in Worldwide (DCP-001)
Active, not recruiting
- Acute Myeloid Leukemia in Remission
- DCP-001
-
Helsinki, Finland
- +9 more
Oct 7, 2022
Cancer, MDS-EB, MDS Trial in Athens, Southampton, Sheffield (INKmune)
Recruiting
- Cancer
- +4 more
- INKmune
-
Athens, Attiki, Greece
- +2 more
Jul 3, 2023
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) Trial in Worldwide (S64315 once a week, S64315 twice a week)
Completed
- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndrome (MDS)
- S64315 once a week
- S64315 twice a week
-
New Haven, Connecticut
- +8 more
May 17, 2022
MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Sydney (Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET,
Recruiting
- Myelodysplastic Syndromes
- +2 more
- Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- Defactinib
-
Sydney, New South Wales, Australia
- +3 more
Jan 12, 2023
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Trial
Not yet recruiting
- Acute Myeloid Leukaemia (AML)
- +2 more
- (no location specified)
Sep 6, 2022
Real World Outcomes Using Novel Agents for AML in the UK
Not yet recruiting
- Acute Myeloid Leukemia
-
London, United KingdomGuy's and St Thomas' NHS Foundation Trust
Mar 28, 2022
Acute Myeloid Leukaemia, Myelodysplasia Trial in Birmingham (Vyxeos, Fludarabine, Busulphan)
Recruiting
- Acute Myeloid Leukaemia
- Myelodysplasia
- Vyxeos
- +4 more
-
Birmingham, United KingdomQueen Elizabeth Hospital
Oct 14, 2021
Acute Myeloid Leukemia (AML) Trial in Nantes (Siltuximab)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
-
Nantes, FranceCHU de Nantes
Jan 24, 2023
Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome Trial in Australia, Netherlands,
Recruiting
- Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome
-
Duarte, California
- +12 more
Jan 4, 2023
Acute Myeloid Leukaemia; MDS;Chronic Myelomonocytic Leukemia Trial in Shenzhen (Azacytidine, HAG Regimen, Azacytidine)
Recruiting
- Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
- Azacytidine, HAG Regimen
- Azacytidine
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Mar 14, 2022
Acute Myeloid Leukemia Trial in Praha (OmnImmune®)
Completed
- Acute Myeloid Leukemia
- OmnImmune®
-
Praha, CzechiaUHKT (Ustav hematologie a krevni transfuze)
Mar 29, 2021
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy Trial in China (APG-2575, reduced-dose HHT, standard-dose HHT)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy
- APG-2575
- +3 more
-
Beijing, Beijing, China
- +9 more
Jan 10, 2022
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Myeloid Leukaemia Trial in United Kingdom (Reduced intensity haplodentical
Active, not recruiting
- Hodgkin's Lymphoma
- +8 more
- Reduced intensity haplodentical stem cell transplant
- Myeloablative haploidentical stem cell transplant
-
Birmingham, United Kingdom
- +11 more
Sep 27, 2021
Acute Myeloid Leukemia, Myelodysplasia Trial in United Kingdom (Oral azacitidine, Matched )
Recruiting
- Acute Myeloid Leukemia
- Myelodysplasia
- Oral azacitidine
- Matched placebo
-
Birmingham, United Kingdom
- +20 more
Oct 14, 2021